Jąkanie a fobia społeczna – główne zagadnienia terapii biologicznej fobii społecznej

• Authors: Czernikiewicz Andrzej , Woźniak Tomasz

Title variants

EN

Stuttering and Social Phobia – the Main Issues Relating to the Biological Therapy of Social Phobia

• Languages of publication: PL

Abstracts

PL

Artykuł przedstawia zależności między jąkaniem i fobią społeczną, towarzyszącą często jąkaniu. W pierwszej części przedstawiono wskazówki diagnostyczne dla fobii społecznej i jąkania. W drugiej części zaprezentowano efekty leczenia fobii społecznej przy użyciu leków psychotropowych, głównie z kręgu leków przeciwdepresyjnych, które to efekty przekładają się na redukcję, a w części przypadków nawet na ustąpienie objawów jąkania. Fakt ten nie oznacza ograniczania terapii osób jąkających się z fobią społeczną tylko do podawania leków. Perspektywa zaprzestania leczenia farmakologicznego i utrzymania stanu poprawy funkcjonowania psychicznego i społecznego pacjenta wymaga nawet stosowania równoległej terapii logopedycznej nastawionej na poprawę płynności mówienia.

EN

The article presents the relationship between stuttering and social phobia, which often accompanies stuttering. The first part presents diagnostic indications for social phobia and stuttering. The second part presents the effects of the treatment of social phobia using psychotropic drugs, mainly the antidepressants, which translate into a reduction, and in some cases even into the alleviation of stuttering symptoms. This fact does not mean limiting the therapy of people who stutter with social phobia to administering drugs. The prospect of discontinuing pharmacological treatment and maintaining the state of improving the patient’s mental and social functioning requires the use of a parallel speech-language therapy aimed at improving fluency of speaking.

Keywords

PL

jąkanie; fobia społeczna; terapia logopedyczna; farmakoterapia

EN

stuttering; social phobia; speech-language therapy; pharmacotherapy

• Publisher: Polskie Towarzystwo Logopedyczne
• Journal: Logopedia
• Year: 2018
• Volume: 47
• Issue: 1
• Pages: 201-213

Dates

published

2020-06-28

Contributors

author

Czernikiewicz Andrzej

• Uniwersytet Marii Curie-Skłodowskiej w Lublinie Zakład Logopedii i Językoznawstwa Stosowanego

author

Woźniak Tomasz

• Uniwersytet Marii Curie-Skłodowskiej w Lublinie Zakład Logopedii i Językoznawstwa Stosowanego

References

• American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders Fifth Edition, Washington.
• Baldwin D.S., Asakura S., Koyama T., Hayano T., Hagino A., Reines E., Larsen K., 2016, Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. Eur Neuropsychopharmacol. Jun, 26(6), s. 1062–9.
• Blanco C., Heimberg R.G., Schneier F.R., Fresco D.M., Chen H., Turk C.L., Liebowitz M.R., 2010, A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry, 67, s. 286–295.
• Blanco C., Bragdon L., Schneier F.R., Liebowitz M.R., 2014, Psychoparmacology for social anxiety disorder, [w:] Social Anxiety Clinical, Developmental, and Social Perspectives, red. S.G. Hoffman, P.M. Di Bartolo, London, s. 626–661.
• Chang S., Zhu D., 2013, Neural network connectivity differences in children who stutter, “Brain”,136, s. 3709–3726.
• Chang S., Zhu D., Choo A., Anstat M., 2015, White matter neuroanatomical differences in young children who stutter, “Brain”, 138, s. 694–711.
• Chouinard G., 2006, The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci, 31(3), s. 168–76.
• Davidson J.R., Potts N.L., Richichi E., Krishnan R., Ford S.M., Smith R., Wilson W.H., 1993, Treatment of social phobia with clonazepam and placebo, „Journal of Clinical Psychopharmacology”, 13, 423–428.
• Davidson J.R., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S., Gadde K.M., 2004, Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia, „Archives of General Psychiatry”, 61, s. 1005–13.
• Fairbanks J., Pine D.S., Tancer N.K., Dummit S.E., Kentgen L.M., Martin J., Klein, R.G., 1997, Open fluoxetine treatment of mixed anxiety disorders in children and adolescents, „Journal of Child and Adolescent Psychopharmacology”, 7, s. 17–29.
• Gelernter C.S., Uhde T.W., Cimbolic P., Arnkoff D.B., Vittone B.J., Tancer M.E., Barto J.J., 1991, Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. „Archives of General Psychiatry”, 48, s. 938–945.
• Gentile S., 2014, Efficacy of antidepressant medications in children and adolescents with nonobsessive-compulsive disorder anxiety disorders: a systematic assessment, „Expert Opin Drug Saf.”, 13(6), s. 735–44.
• Greist JH, Liu-Dumaw M, Schweizer E, Feltner D., 2011, Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study, Int Clin Psychopharmacol, 26(5), s. 243–251.
• Hoffman S.G., Di Bartolo P.M., 2014, Social Anxiety Clinical, Developmental, and Social Perspectives, London.
• Hussain F.S., Dobson E.T., Strawn J.R., 2016, Pharmacologic Treatment of Pediatric Anxiety Disorders, Curr Treat Options Psychiatry, 3(2), s. 151–160.
• Isolan L., Pheula G., Salum G.A., Oswald S., Rohde L.A., Manfro G.G., 2007, An open-label trial of escitalopram in children and adolescents with social anxiety disorder, „Journal of Child and Adolescent Psychopharmacology”, 17, s. 751–759.
• Katschnig H., Stein M.B., Buller R., 1997, On behalf of the International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia: A double-blind, placebo-controlled clinical study, „European Archives of Psychiatry and Clinical Neuroscience”, 247, s. 71–8.
• Lader M., Stender K., Burger V., 2004, Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study, „Depression and Anxiety”, 19, 241–248.
• Liebowitz M.R., 1987, Liebowitz Social Anxiety Scale, „Mod Probl Pharmacopsychiatry”, 22, s. 141–173.
• Liebowitz M.R., Schneier F.R., Campeas R., Hollander E., Hatterer J., Fyer, A., Gully R., 1992, Phenelzine versus atenolol in social phobia: a placebo controlled comparison, „Archives of General Psychiatry”, 49, s. 290–300.
• Liebowitz M.R., DeMartinis N.A., Weihs K. Londborg P.D., Smith W.T. Chung H. Clary, C.M., 2003, Efficacy of sertraline in severe generalized social anxiety disorder: results of a doubleblind, placebo-controlled study, „Journal of Clinical Psychiatry”, 64, s. 785–792.
• Liebowitz M.R., Mangano R.M., Bradwejn, J. Asnis G., 2005, A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder, „Journal of Clinical Psychiatry”, 66, s. 238–247.
• Lydiard R.B., Laraia M.T. Howell E.F., Ballenger J.C., 1988, Alprazolam in the treatment of social phobia, „Journal of Clinical Psychiatry”, 49, 17–19.
• Montgomery S.A., Nil R., Durr-Pal N., Loft H., Boulenger J. P., 2005, A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder, „Journal of Clinical Psychiatry”, 66, s. 1270–1278.
• Nader-Mohammadi Moghadam M., Atef-Vahid M.K., Asgharnejad-Farid A.A., Shabani A., Lavasni F., 2015, Short-term Dynamic Psychotherapy versus Sertraline in Treatment of Social Phobia, Iran J Psychiatry Behav Sci, 9(2) e208.
• Nordahl H.M., Vogel P.A., Morken G., Stiles T.C., Sandvik P., Wells A., 2016, Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial, Psychother Psychosom., 85(6), s. 346–356.
• Nutt D., Ballenger J., 2007, Anxiety disorders: Panic Disorder and social anxiety disorder, Oxford.
• Oh K.S., Shin E., Ha J., Shin D., Shin Y., Lim S.W., 2016, Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study, Clin Psychopharmacol Neurosci. 31, 14(2), s. 161–167.
• Ontiveros, A., 2008, Double–blind controlled study with clonazapam and placebo in social anxiety disorder, Salud Mental, 31, s. 299–306.
• Reich J.R., Yates W., 1988, A pilot study of treatment of social phobia with alprazolam, „American Journal of Psychiatry”, 145, s. 590–594.
• Rynn M.A., 2001, Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder, „American Journal of Psychiatry”, 158, s. 2008–2014.
• Schneier F.R. (1995). Clinical assessment strategies for social phobia, „Psychiatric Annals”, 25, s. 550–553.
• Schneier F.R., Goetz D., Campeas R., Fallon B., Marshall R., Liebowitz M.R., 1998, Placebo-controlled trial of moclobemide in social phobia, „British Journal of Psychiatry”, 172, s. 70–77.
• Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R.,Dunbar G.C., 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD10. J Clin Psychiatry, 59 Suppl 20, s. 22–33.
• Simon N.M., Worthington J.J., Moshier S.J., Marks E.H., Hoge E.A., Brandes M., Delong H., Pollack M.H., 2010, Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response, CNS Spectr., 15(7): s. 367–73.
• Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I., 1998, Paroxetine treatment of generalized social phobia (social anxiety disorder), JAMA 280, s. 708–713.
• Stein D.J., Cameron A., Amrein R., Montgomery S.A., 2002, Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder, „International Journal of Clinical Psychopharmacology”, 17, 161–170.
• Stein D.J., Versiani M., Hair T., Kumar R., 2002a, Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study, „Archives of General Psychiatry”, 59, s. 1111–1118.
• Stein M.B., Pollack. M.H., Bystritsky A., Kelsey J.E., Mangano R.M., 2005, Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology, 177, s. 280–288.
• Turner S.M., Beidel D.C., Jacob R.G., 1994, Social phobia: a comparison of behavior therapy and atenolol, „Journal of Consulting and Clinical Psychology”, 62, s. 350–358.
• Van Ameringen M.A., Lane R.M., Walker J.R., Bowen R.C., Chokka P.R., Goldner E.M., Swinson R.P., 2001, Sertraline treatment of generalized social phobia: a 20-week, doubleblind, placebo-controlled study, „American Journal of Psychiatry”, 158, s. 275–281.
• Versiani M., Mundim F.D., Nardi A.E., Liebowitz M.R., 1988, Tranylcypromine in social phobia, „Journal of Clinical Psychopharmacology”, 8, s. 279–283.
• Westenberg H.G., Stein D.J., Yang H., Li D., Barbato L.M., 2004, A double-blind placebocontrolled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder, „Journal of Clinical Psychopharmacology”, 24, s. 49–55.
• Woźniak T., 2015, Diagnoza i terapia osób z zaawansowanym jąkaniem, [w:] Logopedia. Standardy postępowania logopedycznego, red. S. Grabias, J. Panasiuk, T. Woźniak, Lublin, s. 797–83.